An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial

American Heart Journal

Volumn 200, Issue , 2018, Pages 17-23

  Lopes, Renato D ^a   Vora, Amit N ^a   Liaw, Danny ^b   Granger, Christopher B ^a   Darius, Harald ^c   Goodman, Shaun G ^d,e   Mehran, Roxana ^f   Windecker, Stephan ^g   Alexander, John H ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c Vivantes Neukoelln Medical Center   (Germany)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^g BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; PLACEBO; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG SAFETY; FACTORIAL DESIGN; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STENT THROMBOSIS; ADULT; AGED; BLEEDING; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; FEMALE; MALE; MIDDLE AGED; PATIENT SELECTION; PROCEDURES; RISK FACTOR; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PYRAZOLES; PYRIDONES; RISK FACTORS; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 85044966487     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2018.03.001     Document Type: Article

References (29)

1. Chugh, S.S., Havmoeller, R., Narayanan, K. et al., Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation 129 (2014), 837–847.
2. Baseline characteristics of patients with atrial fibrillation: the AFFIRM study. Am Heart J, 143, 2002, 991–1001.
3. Capodanno, D., Angiolillo, D.J., Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circ Cardiovasc Interv 7 (2014), 113–124.
4. Rubboli, A., Colletta, M., Herzfeld, J. et al., Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention. Coron Artery Dis 18 (2007), 193–199.
5. Wang, T.Y., Robinson, L.A., Ou, F.S. et al., Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J 155 (2008), 361–368.
6. Pérez-Gómez, F., Alegría, E., Berjón, J. et al., Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 44 (2004), 1557–1566.
7. Lip, G.Y., Huber, K., Andreotti, F. et al., Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost 103 (2010), 13–28.
8. Leon, M.B., Baim, D.S., Popma, J.J. et al., A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 339 (1998), 1665–1671.
9. Connolly, S., Pogue, J., Hart, R. et al., Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 (2006), 1903–1912.
10. Sorensen, R., Hansen, M.L., Abildstrom, S.Z. et al., Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 374 (2009), 1967–1974.
11. Hansen, M.L., Sorensen, R., Clausen, M.T. et al., Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170 (2010), 1433–1441.
12. Dewilde, W.J., Oirbans, T., Verheugt, F.W. et al., Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 381 (2013), 1107–1115.
13. January, C.T., Wann, L.S., Alpert, J.S. et al., 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), e1–76.
14. Levine, G.N., Bates, E.R., Bittl, J.A. et al., 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 68 (2016), 1082–1115.
15. Kirchhof, P., Benussi, S., Kotecha, D. et al., 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37 (2016), 2893–2962.
16. Gibson, C.M., Mehran, R., Bode, C. et al., Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 375 (2016), 2423–2434.
17. Cannon, C.P., Bhatt, D.L., Oldgren, J. et al., Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377:16 (2017), 1513–1524.
18. Lopes, R.D., Alexander, J.H., Al-Khatib, S.M. et al., Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 159 (2010), 331–339.
19. Granger, C.B., Alexander, J.H., McMurray, J.J. et al., Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365 (2011), 981–992.
20. Alexander, J.H., Lopes, R.D., Thomas, L. et al., Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 35 (2014), 224–232.
21. Alexander, J.H., Lopes, R.D., James, S. et al., Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365 (2011), 699–708.
22. Connolly, S.J., Ezekowitz, M.D., Yusuf, S. et al., Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
23. Patel, M.R., Mahaffey, K.W., Garg, J. et al., Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
24. Giugliano, R.P., Ruff, C.T., Braunwald, E. et al., Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369 (2013), 2093–2104.
25. Roe, M.T., Armstrong, P.W., Fox, K.A. et al., Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 367 (2012), 1297–1309.
26. Mega, J.L., Braunwald, E., Wiviott, S.D. et al., Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366 (2012), 9–19.
27. Mauri, L., Kereiakes, D.J., Yeh, R.W. et al., Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371 (2014), 2155–2166.
28. Vranckx, P., Lewalter, T., Valgimigli, M. et al., Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial. Am Heart J 196 (2018), 105–112.
29. Hoshi, T., Sato, A., Nogami, A. et al., Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. J Cardiol 69 (2017), 648–651.